Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment
about
An update on the use of transdermal oxybutynin in the management of overactive bladder disorderIntravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract SurgeryBotulinum toxin A for the Treatment of Overactive BladderAnticholinergic medication use and dementia: latest evidence and clinical implicationsCorrelation between overactive bladder symptom score and neuropsychological parameters in Alzheimer's disease patients with lower urinary tract symptom.Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies.Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis.Efficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis.Protocol for a prospective observational study of cortical lower urinary tract control changes following intradetrusor injection of botulinum toxin-A in patients with multiple sclerosisAssociation between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus.The Burden of Overactive Bladder on US Public HealthUnderactive bladder in women: is there any evidence?The attitudes of Urologists and Gynecologists about overactive bladder and treatment of it in Turkey: A questionnaire survey.Urogynecological conditions associated with overactive bladder symptoms in women.Tibial nerve stimulation to inhibit the micturition reflex by an implantable wireless driver microstimulator in cats.Current and potential urological applications of botulinum toxin A.Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.The impact of persistence with mirabegron usage versus switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.Delivery methods for drugs used in the treatment of overactive bladder.Schooling impacts on the overactive bladder diagnosis in women.The role of acupuncture in managing overactive bladder; a review of the literature.Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States.Where Are We Headed with Neuromodulation for Overactive Bladder?Urinary incontinence in men: current and developing therapy options.Prevention of pelvic floor disorders: international urogynecological association research and development committee opinion.Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015).Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement.Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder: A 3-Year Follow-up Study.Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.Management of device-related complications after sacral neuromodulation for lower urinary tract disorders in women: a single center experience.Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.The impact of prior back surgery on neuromodulation outcomes: A review of over 500 patients.Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.Evaluation of the axonics modulation technologies sacral neuromodulation system for the treatment of urinary and fecal dysfunction.A Systematic Approach to the Evaluation and Management of the Failed Artificial Urinary Sphincter.Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.Differences in the Association of Nocturia and Functional Outcomes of Sleep by Age and Gender: A Cross-sectional, Population-based Study.Incidence and Management of Lower Urinary Tract Symptoms After Urethral Stricture Repair.
P2860
Q26749105-C9903E07-4F59-49D5-A3A3-CB8E939E140AQ26749608-E52DC132-E1F8-4E57-B13C-EDF5781F950BQ26764765-7E2016F5-94FE-49BA-A21B-7D8D2046B8ECQ28068339-86F4BA91-C153-4DE4-B0AA-8400B5D82FD7Q33692634-0D8412A7-F4DD-4764-B2A4-EDD8D983DE0CQ33696642-9689D443-92E7-4A71-B365-80BE40D17CACQ33727733-F5D35FA3-5C38-4ACE-9D79-94E1A90A9F5AQ35839133-BEBE6525-90D2-4030-BC2F-8F684211D3E0Q36006813-DF14D536-1C47-41AB-9D90-7EBC0F301CA0Q36270494-E066B3D4-DCA5-4092-AF50-967721D37ED0Q36338313-11126FFC-41AA-4B60-A33A-BB9E62C1C082Q36767014-4C453F23-3F1E-4904-BA01-49837948066AQ36968506-4986EC11-9744-4E38-81E1-F860DF60518DQ37671608-8F511192-5B39-41AB-8BEB-C842F846AF71Q37720755-A5374576-5955-485E-BE34-B0163BA81399Q37726710-C37B0594-CCCD-427B-8691-F1CBF50F777FQ38564108-29CC512F-DCD4-4528-8E8E-748E7FEECCC0Q38570412-E8AA9CA0-00D1-449C-89DA-86B3CD198AFFQ38577301-B1203830-BD1A-4477-8C09-4BD596F9FC89Q38626236-39EBFE4D-0885-446B-A589-65FDE0EEAFA4Q38665319-0A9EFBDD-D682-4E2F-9341-67C185902AD2Q38670317-1EB0838C-89F7-497B-9917-BBE37F6E6842Q38689041-3C5B4FC3-FA0F-4CD8-A36A-F6A15A78547DQ38689480-CC67A615-A166-41EC-A83B-252A4CEC955CQ38705823-FA3ABAB8-881E-444F-9C9D-A7590DE93910Q38708104-98C9C8B9-1A8E-4505-8E46-F15E5327BE47Q38771985-BC6A4517-92CB-4A81-9D83-DE2D42AFD362Q38819016-0371F306-7231-4DB1-9D2A-EFC92EEF0A77Q38845396-59DF1F7A-94EA-47AE-AA65-903CC730A5E7Q38853682-53E8F032-1EAA-4C08-9227-29E32FC0FD7AQ38911819-C6E003F7-19D9-40B6-A751-88AA668E04C5Q38931839-F3FF01B3-7525-4617-9BDF-12A21252E36EQ38950244-DD14B43B-E592-431D-BB42-6F155CC2ED00Q38965886-9D2FFD5D-2B14-4ADA-AD3E-E42D4DB57EC9Q39020998-55590EC9-81B1-4F58-8AED-97735D365BE7Q39028663-DD1CBD8E-3D74-471E-A543-348140E78BF7Q39148870-47DE347A-9B11-4B18-BD59-A739F100A181Q39176604-75C088F3-43E3-4BE4-A856-A51EB3040506Q39280516-70AA86DE-9F85-4871-8F95-E523FCB3E69CQ39441072-6CE40037-132A-4F7B-9FC9-7B38C987D246
P2860
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Diagnosis and treatment of ove ...... : AUA/SUFU guideline amendment
@ast
Diagnosis and treatment of ove ...... : AUA/SUFU guideline amendment
@en
Diagnosis and treatment of ove ...... : AUA/SUFU guideline amendment
@nl
type
label
Diagnosis and treatment of ove ...... : AUA/SUFU guideline amendment
@ast
Diagnosis and treatment of ove ...... : AUA/SUFU guideline amendment
@en
Diagnosis and treatment of ove ...... : AUA/SUFU guideline amendment
@nl
prefLabel
Diagnosis and treatment of ove ...... : AUA/SUFU guideline amendment
@ast
Diagnosis and treatment of ove ...... : AUA/SUFU guideline amendment
@en
Diagnosis and treatment of ove ...... : AUA/SUFU guideline amendment
@nl
P2093
P3181
P1476
Diagnosis and treatment of ove ...... : AUA/SUFU guideline amendment
@en
P2093
Deborah J Lightner
E Ann Gormley
Martha Faraday
Sandip Prasan Vasavada
P304
P3181
P356
10.1016/J.JURO.2015.01.087
P407
P577
2015-05-01T00:00:00Z